New Data suggest COVAXIN (BBV152) may provide protection against current and future variants!
data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant.
52 Week Range 0.28 - 18.77
My price target is the 10.30usd resistance.
